Status:
UNKNOWN
Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular Carcinoma
Lead Sponsor:
Sir Salimullah Medical College Mitford Hospital
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Hepatocellular carcinoma is the most common type of liver cancer, which is the 3rd leading cause of cancer deaths worldwide. The incidence is expected to increase as a consequence of chronic liver dis...
Detailed Description
1. Introduction: Hepatocellular carcinoma is one of the most common type of liver cancer, which is the 3rd leading cause of cancer deaths worldwide. The incidence is expected to increase as a cons...
Eligibility Criteria
Inclusion
- 1\. Patients with Hepatocellular Carcinoma (Diagnosed histologically or cytologically or by imaging criteria with CT or MRI) with no option of resectibility (BCLC stage B or C) 2. Age ≥ 18 years
Exclusion
- \- 1. Patients with very early stage Hepatocellular Carcinoma (BCLC stage 0) 2. Patients with early stage Hepatocellular Carcinoma (BCLC stage A) 3. Patients with terminal stage Hepatocellular Carcinoma (BCLC stage D) 4. Patients with Hepatocellular Carcinoma with obvious invasion to bile duct. 5. Patients who received previous systemic therapy for Hepatocellular Carcinoma.
- 7\. Patients with jaundice (serum bilirubin ≥ 3 mg/dl) 8. Patients with aminotransferases ≥ 5ULN 8. Patients with other co-morbid conditions (COPD, CKD, Heart failure, IHD, pregnancy)
Key Trial Info
Start Date :
January 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2023
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT05391867
Start Date
January 1 2022
End Date
June 30 2023
Last Update
May 26 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Hepatology
Dhaka, Bangladesh, 1100
2
Sir Salimullah Medical College
Dhaka, Bangladesh, 1100